Dynavax appoints new chief medical officer
Janssen used to serve as Dynavax's vice president of medical affairs, a position he has held since November 2012. Before that, he was Dynavax's senior director of clinical development, which he held from 2010 until his appointment as vice president of medical affairs.
"Rob has proven an invaluable member of the management team and we look forward to his ongoing contributions to the organization," Eddie Gray, Dynavax's chief executive officer, said.
Before joining Dynavax, Janssen was vice president of medical affair at Gilead, where he was responsible for oversight of physician and health care provider education. For 23 years, Janssen was at the U.S. Centers for Disease Control and Prevention. At the CDC, Janssen looked into HIV treatment as a mode of HIV prevention.
Janssen is a neurologist with training in virology. He has published over 130 scientific articles in numerous journals, and has served as a reviewer for leading scientific journals.
Dyanvax is a clinical-stage biopharmaceutical company that develops novel products aimed at treating infectious diseases. Dynavax's leading product is HEPLISAV, an adult hepatitis B vaccine.